132 related articles for article (PubMed ID: 14613343)
1. The cost of treating osteoporosis in a managed health care organization.
Desai SS; Duncan BS; Sloan AS
J Manag Care Pharm; 2003; 9(2):142-9. PubMed ID: 14613343
[TBL] [Abstract][Full Text] [Related]
2. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
3. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
4. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years.
Newman ED; Ayoub WT; Starkey RH; Diehl JM; Wood GC
Osteoporos Int; 2003 Apr; 14(2):146-51. PubMed ID: 12730773
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
7. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
10. Management of osteoporosis in women aged 50 and older with osteoporosis-related fractures in a managed care population.
Gunter MJ; Beaton SJ; Brenneman SK; Chen YT; Abbott TA; Gleeson JM
Dis Manag; 2003; 6(2):83-91. PubMed ID: 14577902
[TBL] [Abstract][Full Text] [Related]
11. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture.
Andrade SE; Majumdar SR; Chan KA; Buist DS; Go AS; Goodman M; Smith DH; Platt R; Gurwitz JH
Arch Intern Med; 2003 Sep; 163(17):2052-7. PubMed ID: 14504118
[TBL] [Abstract][Full Text] [Related]
12. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
Viswanathan HN; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Wade SW
Appl Health Econ Health Policy; 2012 May; 10(3):163-73. PubMed ID: 22510025
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study.
Häussler B; Gothe H; Göl D; Glaeske G; Pientka L; Felsenberg D
Osteoporos Int; 2007 Jan; 18(1):77-84. PubMed ID: 17048064
[TBL] [Abstract][Full Text] [Related]
14. Actuarial analysis of private payer administrative claims data for women with endometriosis.
Mirkin D; Murphy-Barron C; Iwasaki K
J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
[TBL] [Abstract][Full Text] [Related]
15. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
16. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation.
Ray NF; Chan JK; Thamer M; Melton LJ
J Bone Miner Res; 1997 Jan; 12(1):24-35. PubMed ID: 9240722
[TBL] [Abstract][Full Text] [Related]
17. Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom.
Gutiérrez L; Roskell N; Castellsague J; Beard S; Rycroft C; Abeysinghe S; Shannon P; Gitlin M; Robbins S
Bone; 2012 Sep; 51(3):324-31. PubMed ID: 22684000
[TBL] [Abstract][Full Text] [Related]
18. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
Cotté FE; Mercier F; De Pouvourville G
Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
[TBL] [Abstract][Full Text] [Related]
19. The cost of treating osteoporotic fractures in the United Kingdom female population.
Dolan P; Torgerson DJ
Osteoporos Int; 1998; 8(6):611-7. PubMed ID: 10326069
[TBL] [Abstract][Full Text] [Related]
20. Making the most of managed care dollars spent for postmenopausal osteoporosis.
Ettinger B
Manag Care Interface; 2005 Dec; 18(12):55-9. PubMed ID: 16405226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
